Privia Health Group (PRVA.O): 2Q26 Recap: A Solid Quarter Across the Board; Prudent Guidance Portends Additional Beats and Raises

Research evidence excerpt

Vi ewp oint |

06 Aug 2026 12:46:14 ET │ 15 pages

Privia Health Group (PRVA.O)

2Q26 Recap: A Solid Quarter Across the Board; Prudent Guidance

Portends Additional Beats and Raises

CITI'S TAKE

PRVA delivered a strong 2Q, beating expectations across the board with

Practice Collections up 12.4% y/y, Attributed Lives up 19.2% y/y, and Adj.

EBITDA up 29.1% y/y with margins expanding 310bps to 28.3%

(approaching PRVA’s LT 30–35% target). Mgmt. was constructive on

ambulatory utilization trends and characterized the shared savings

performance as reflective of genuine medical cost management. Despite

the clean beat, the stock is down ~11%, which we view as an overreaction

driven by the implied 2H deceleration embedded in the updated guidance.

Importantly, mgmt. explicitly attributed this to conservatism and

highlighted upside if trends continue. This is consistent with PRVA's 21quarter track record of beats and raises. With Attributed Lives raised above

the prior high end to 1.625M–1.650M, the Evolent/Care Partners ACO

platform ramping, and AI-driven margin expansion, our Buy thesis remains

firmly intact, and we view this as a buying opportunity.

n

Buy

Price (05 Aug 26 16:00)

US$23.96

Target price

US$35.00

Expected share price return

46.1%

Expected dividend yield

0.0%

Expected total return

46.1%

Market Cap

US$3,019M

Price Performance

(RIC: PRVA.O, BB: PRVA US)

Results — PRVA reported a strong quarter with particular FFS strength. Practice

Collections grew +12.4% y/y and beat our/cons. estimates by ~5%/4%, driven by

10.1% Implemented Provider growth and robust ambulatory volumes. FFS-Patient

Care beat our/cons. by 4.3%/6.9%, while FFS-Administrative Services missed by

(2.3%)/(1.8%). On the VBC side, Capitated Revenue of $95.2M (+26.0% y/y) beat

our/cons. by 16.0%/15.5% and Care Mgmt. Fees beat by 13.5%/8.5%, while Shared

Savings missed by (3.2%)/(2.4%). Attributed Lives of 1,647K (+19.2% y/y) beat

our/cons. by 2.4%/3.5%. Profitability, too, was impressive as Care Margin beat

our/cons. by 1.6%, and Platform Contribution beat by 2.9%/4.1% (as cost of platform

declined ~400 bps y/y). Adj. EBITDA of $37.4M slightly missed our estimate of

$38.0M but beat cons. of $36.6M.

…